Interim Report 2026
Filed with HKEX · Stock code 1244 · · 110 pages · English and Chinese
2 Definitions 8 Corporate Information 11 Business Highlights 17 Financial Summary 21 Management Discussion and Analysis 65 Other Information 84 Independent Review Report 釋義公司資料業務摘要財務概要管理層討論及分析其他資料獨立審閱報告 86 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 中期簡明綜合損益及其他全面收益表 87 Interim Condensed Consolidated Statement of Financial Position 中期簡明綜合財務狀況表 89 Interi
Earlier from 3D Medicines
- Discloseable transaction
- 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
- 3D Medicines Inc Says Zhang Jing Resigns As CFO
- 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
- 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Later from 3D Medicines
- Change of principal share registrar and transfer office
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement latest progress in collaboration programs: achievement of pre-specified number of events in the global pivotal phase 3 regal trial for 3D189
Follow 3D Medicines into a list and get an email when it puts out news.
Follow 3D Medicines